Drugs Made In America Acquisition Corp. DMAA FINANCIAL
Company Overview
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -17.9%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -17.90% |
Stock Price Performance
| 1 Year: | +5.27% |
| 6 Months: | +3.06% |
| 3 Months: | +1.60% |
| 1 Month: | +0.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)76.86 · Overbought
P/E of 59.94 is above the sector median of 12.89 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 59.9.
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DMAA Drugs Made In America Acquisition Corp. FINANCIAL | 10.79 | 59.94 | $261.95M | 0.00% | -1.18% | -81.78% | - | - |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Income | -144.93K | -330.93K | -131.92K | -263.70K | -143.30K |
| Net Income | -144.93K | 1.25M | 2.29M | 2.18M | 1.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Income | -2.82M |
| Net Income | 5.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 550.82K | 239.92M |
| Total Equity | -244.84K | -7.26M |
| Total Liabilities | 795.67K | 7.28M |
| Current Liabilities | 795.67K | 376.17K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -539.19K |
| Investing Cash Flow | -231.15M |
| Financing Cash Flow | 231.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | -81.8% |
| ROCE % | -1.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Karpus Management, Inc. | 10.33% | 2.51M | $27.18M |
| 2 | Mizuho Securities USA LLC | 8.52% | 2.07M | $22.43M |
| 3 | Polar Asset Management Partners Inc. | 4.72% | 1.15M | $12.42M |
| 4 | Glazer Capital LLC | 4.12% | 999.90K | $10.84M |
| 5 | Wolverine Asset Management, LLC | 3.43% | 832.09K | $9.02M |
| 6 | Highbridge Capital Management, LLC. | 3.33% | 809.05K | $8.77M |
| 7 | First Trust Capital Management L.P. | 3.24% | 786.46K | $8.53M |
| 8 | Heights Capital Management, Inc | 2.67% | 648.08K | $7.03M |
| 9 | Westchester Capital Management, LLC | 2.40% | 581.79K | $6.31M |
| 10 | Clear Street Group Inc. | 1.58% | 382.44K | $4.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMAA
Mizuho Financial Group (DMAA) discloses 8.5% beneficial stake in SPAC - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOOXFBQ2RtdnMyWXB2aF8tY1pXc3dCN2IzVFdQRm9ydllOdjMta2d2YVRvVk02dVlFRkg2WF9jc2I4WFpQQnA4ZHBWZ2NELV9FYWs4ajQ5THRoZk55anJvRGE2TVpwQ3FXYnpOYTNGN2h4U08zS1NyVTM4X2ZFNkdiaU1DR0Rma2dzZ3NKTE…
Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Down 0% - Should You Sell? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPdlg5WklVRnYwa1BxQWZ4cUFDWkJzOVk1TmZsblJQLWtMU1BfYzlkYzFZbm9IdUlreUM5Vk5xaWFWVzZuNDFQWjRuVVFTWEVMaUhDbm5GSmRJaDNvZkgtSTJJRzJKNkNFZjU3TTB2a0pwZlhZdmdibVVabnJNZ1lEVjNBU2t6ajRESndrMF…
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Drugs Made In America Acquisition Corp. (NASDAQ: DMAA) - Morningstar
<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxNYUx6Z1Z1QmVmdXJ0cENneVRub0VMMTFuNGxCd0o3RFBYbkczX1RxZ3ZhUU5GMlBBNXdmd0tzRTRlaEk1ZklDNWFrbG5iNHlRazJXMy1HU2tiNWt5SDR1eGJjUHl3TUI3Mi1Od01PQkUyVy1UYVFuTzYtUERfeUZDZE16U3NnR0lQRnc4eW…
DMAA Price Today: {{stockName}} Stock Price, Quote & Chart | MEXC - MEXC
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE1NbHNzREl5Vk5Eb2hXZ1dqSWZrZlVRTU9KZ3dtSHI0T1Z2QVo1RjNfU0JjY3d2YlhUbHFRU29ZdHhYWGs1X2tJ?oc=5" target="_blank">DMAA Price Today: {{stockName}} Stock Price, Quote & Chart | MEXC</a>&n…
Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics - Investing.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVGhZakR2ZW5iU2FSYzNCU2xCbVlaWFFRb3NtZmlhS1hNR3lTR1pPUk5xWktubmg3NV9MaUM4VGRIUkRFZ2o5VGthZTIyci1RcWhDSkRIaGFHWTNMZmRaZm41RUZfT0hDSk83YmYtemdTbmxxT2lZci1TN3NwWVRwV3Q2akE2a0ZtOHNVRE…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE03ZGpqeXNtdjZOLXUwbXZpeGoxYWdqRVJSTXRia1prRGtpMFE3VldVMUpTWFJnYS1NNm00bHN3V1JOZklXdjFJaGlKMGdMSTdz?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
DMAA — Frequently Asked Questions
What is the current share price of Drugs Made In America Acquisition Corp. (DMAA)?
As of 2026-09-19 21:16 PDT, Drugs Made In America Acquisition Corp. (DMAA) trades at $10.79 on NasdaqGM. Its 52-week range is $10.25 to $10.79.
What is the market capitalisation of DMAA?
Drugs Made In America Acquisition Corp. (DMAA) has a market capitalisation of $261.95M on NasdaqGM.
What is the P/E ratio of DMAA?
DMAA trades at a trailing price-to-earnings (P/E) ratio of 59.94. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is -35.41.
What is the return on equity (ROE) of DMAA?
DMAA has a return on equity (ROE) of -81.78%. Its return on capital employed (ROCE) is -1.18%.
Is DMAA a good stock to buy?
This page provides a data-driven analysis of Drugs Made In America Acquisition Corp. (DMAA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.